Track topics on Twitter Track topics that are important to you
Teva has released its second quarter financials and they do not make for great reading if you’re an investor. The company announced a $6 billion loss, though this can be attributed to a $6.1 billion goodwill impartment charge over its Allergan acquisition.
What will have worried investors more is that adjusted net income fell below market expectations ($1 billion instead of $1.1 billion) and coincided with the release of news that it plans to scale back its global operations due to the difficulties it is facing.
Original Article: Teva releases financials, shares fall off cliff, plans to axe 7000 jobsNEXT ARTICLE
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...
Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...